Is Autolus Therapeutics Ltd (AUTL) overvalued? · rev $10.1M
Autolus Therapeutics Ltd (AUTL) is a biotechnology company listed on US.
This page asks whether Autolus Therapeutics Ltd (AUTL) looks expensive on cached numbers — not a short thesis.
Latest reported AUTL revenue for 2024-12-31 was $10.1M. Net income was -$220.7M. Revenue was up 496.0% from 2023-12-31 to 2024-12-31. AUTL currently screens at market cap $614.8M.
AUTL currently screens at market cap $614.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AUTL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AUTL stock page for the full model, not this heading.
Not investment advice.